Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
1. A conjugated nucleic acid molecule which has the following formula:
wherein N is a nucleotide, n is an integer from 15 to 195, the underlined N refers to a nucleotide having or not a modified phosphodiester backbone, L′ is a linker; m is 1 and L is a linker, C is a molecule facilitating endocytosis selected from the group consisting of single or double chain fatty acids, tocopherol, folates or folic acid, cholesterol, sugar, peptide and protein, and wherein C is conjugated via L to the 5′ end of the nucleic acid molecule.
2. The conjugated nucleic acid molecule according to claim 1 , wherein n is 27.
3. The conjugated nucleic acid molecule according to claim 1 , wherein C is selected from the group consisting of tocopherol and cholesterol.
4. The conjugated nucleic acid molecule according to claim 1 , wherein L′ is a loop linking the two strands of the nucleic acid molecule.
5. The conjugated nucleic acid molecule according to claim 1 , wherein L′ is selected from the group consisting of a nucleotide linker and a non-nucleotide linker.
6. The conjugated nucleic acid molecule according to claim 5 , wherein L′ is a non-nucleotide linker selected from the group consisting of abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon and polymeric compounds.
7. The conjugated nucleic acid molecule according to claim 5 , wherein L′ is selected from the group consisting of hexaethyleneglycol, tetradeoxythymidylate (T4), 1,19-bis(phospho)-8-hydraza-2-hydroxy-4-oxa-9-oxo-nonadecane and 2,19-bis(phosphor)-8-hydraza-1-hydroxy-4-oxa-9-oxo-nonadecane.
8. The conjugated nucleic acid molecule according to claim 1 , wherein L is selected from the group consisting of aliphatic chain, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, polymeric compounds and compounds incorporating a disulfide linkage, a protected disulfide linkage, an amide linkage, an acid labile linkage, an ester linkage, an ortho ester linkage, a phosphonamide linkage, a biocleavable peptide linkage, an azo linkage and an aldehyde linkage.
9. The conjugated nucleic acid molecule according to claim 8 , wherein L is selected from the group consisting of an oligoethylene glycol and a dialkyl-disulfide.
10. The conjugated nucleic acid molecule according to claim 1 , wherein the molecule is
with 3 phosphorothioate internucleotide linkages at each of the 5′ and the 3′ ends.
11. A pharmaceutical composition comprising a conjugated nucleic acid molecule according to claim 1 .
12. The pharmaceutical composition according to claim 11 , wherein said composition further comprises a DNA-damaging anti-tumoral agent and a pharmaceutically acceptable carrier.
13. A kit comprising a conjugated nucleic acid molecule according to claim 1 and a DNA-damaging anti-tumoral agent, as a combined preparation for simultaneous, separate or sequential use.
14. A method for treating a cancer in a subject in need thereof, comprising administering an effective amount of conjugated nucleic acid molecule of claim 1 .
15. The method according to claim 14 , wherein the treatment further comprises radiotherapy or chemotherapy, optionally with a DNA damaging antitumoral agent.